SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gaspar Esquerdo Galiana, Jose Manuel Cervera, Enrique Barrajón, Asunción Juárez, Cristina Llorca, Nieves Díaz, Antonio López, Rafael Peiró, Association between serum levels of C-reactive protein and response to treatment of chemotherapy-induced anemia in patients with solid tumors: a multicenter, prospective, observational study, Medical Oncology, 2013, 30, 1

    CrossRef

  2. 2
    Johan Vansteenkiste, Isabelle Wauters, Steven Elliott, John Glaspy, Michael Hedenus, Chemotherapy-induced anemia: the story of darbepoetin alfa, Current Medical Research and Opinion, 2013, 29, 4, 325

    CrossRef

  3. 3
    Robert Pirker, Melissa Pirolli, Jane Quigley, Scott Hulnick, Jason Legg, Helen Collins, Johan Vansteenkiste, Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent, Supportive Care in Cancer, 2013, 21, 4, 987

    CrossRef

  4. 4
    Michael Hedenus, Anders Österborg, Dianne Tomita, Chet Bohac, Bertrand Coiffier, Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis, Leukemia & Lymphoma, 2012, 53, 11, 2151

    CrossRef

  5. 5
    Aurelia Bustos, Ruth Álvarez, Pedro Miguel Aramburo, Francisco Carabantes, Nieves Díaz, Jesús Florián, Martín Lázaro, José María Martín de Segovia, José Antonio Gasquet, Adrián Alegre, Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia, Current Medical Research and Opinion, 2012, 28, 1, 57

    CrossRef

  6. 6
    A. Villegas, B. Arrizabalaga, C. Fernández-Lago, M. Castro, J.R. Mayans, J.R. González-Porras, R.F. Duarte, A.F. Remacha, E. Luño, J.A. Gasquet, Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response, Current Medical Research and Opinion, 2011, 27, 5, 951

    CrossRef

  7. 7
    J Glaspy, J Crawford, J Vansteenkiste, D Henry, S Rao, P Bowers, J A Berlin, D Tomita, K Bridges, H Ludwig, Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes, British Journal of Cancer, 2010, 102, 2, 301

    CrossRef

  8. 8
    Y. Ichinose, T. Seto, Y. Nishiwaki, Y. Ohe, Y. Yamada, K. Takeda, N. Saijo, T. Hotta, Randomized Phase 2 Dose-finding Study of Weekly Administration of Darbepoetin Alfa in Anemic Patients with Lung or Ovarian Cancer Receiving Multicycle Platinum-containing Chemotherapy, Japanese Journal of Clinical Oncology, 2010, 40, 6, 521

    CrossRef

  9. 9
    R. Ravasio, G. Bernardo, C. Cerra, P. Fratino, Analisi di minimizzazione dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia indotta da chemioterapia, PharmacoEconomics Italian Research Articles, 2009, 11, 1, 15

    CrossRef

  10. 10
    Frank Schaarschmidt, Egbert Biesheuvel, Ludwig A. Hothorn, Asymptotic Simultaneous Confidence Intervals for Many-to-One Comparisons of Binary Proportions in Randomized Clinical Trials, Journal of Biopharmaceutical Statistics, 2009, 19, 2, 292

    CrossRef

  11. 11
    Vicente Alberola Candel, Alfredo Carrato Mena, Eduardo Díaz-Rubio García, Pere Gascón Vilaplana, Manuel González Barón, Miguel Martín Jiménez, Emilio Alba Conejo, Javier Cassinello Espinosa, Ramon Colomer, Juan Jesús Cruz Hernández, Agustí Barnadas i Molins, Carlos Camps Herrero, Ana Ma. Casas Fernández de Tejerina, Joan Carulla Torrent, Manuel Constenla Figueiras, Joaquin Gavilá Gregori, Ma. Dolores Isla Casado, Bartomeu Massuti Sureda, Mariano Provencio Pulla, César Augusto Rodríguez Sánchez, Jaime Sanz Ortiz, Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients, Clinical and Translational Oncology, 2009, 11, 11, 727

    CrossRef

  12. 12
    Nadine Shehata, Irwin Walker, Ralph Meyer, Adam E Haynes, Kevin Imrie, The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review, Annals of Hematology, 2008, 87, 12, 961

    CrossRef

  13. 13
    Vuslat YURUT-CALOGLU, Murat CALOGLU, Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy, Asia-Pacific Journal of Clinical Oncology, 2008, 4, 4
  14. 14
    Dusan Kotasek, Jean-Luc Canon, Maria Victoria Mateos, Michael Hedenus, Greg Rossi, Kerry Taylor, A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia*, Current Medical Research and Opinion, 2007, 23, 6, 1387

    CrossRef

  15. 15
    Johan Vansteenkiste, Isabelle Wauters, Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals, Expert Review of Anticancer Therapy, 2007, 7, 10, 1347

    CrossRef

  16. 16
    Morgan Milano, Maurice Schneider, EPO in cancer anemia: Benefits and potential risks, Critical Reviews in Oncology/Hematology, 2007, 62, 2, 119

    CrossRef

  17. 17
    Paul Cornes, Bertrand Coiffier, Jean-Jacques Zambrowski, Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option, Current Medical Research and Opinion, 2007, 23, 2, 357

    CrossRef

  18. 18
    A. Pelegrí, Impact of erythropoietin treatment on the quality of life of oncologic patients, Clinical and Translational Oncology, 2007, 9, 10, 645

    CrossRef

  19. 19
    Carsten Oberhoff, Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins, Supportive Care in Cancer, 2007, 15, 6, 603

    CrossRef

  20. 20
    Susan D. Ross, I. Elaine Allen, David H. Henry, Christopher Seaman, Brian Sercus, Lawrence T. Goodnough, Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature, Clinical Therapeutics, 2006, 28, 6, 801

    CrossRef

  21. 21
    B. Reichardt, Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting, Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 5
  22. 22
    M Asif A Siddiqui, Gillian M Keating, Darbepoetin??Alfa, Drugs, 2006, 66, 7, 997

    CrossRef

  23. 23
    Isabelle Wauters, Karin Pat, Johan Vansteenkiste, Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia, Therapeutics and Clinical Risk Management, 2006, 2, 2, 175

    CrossRef

  24. 24
    J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, J. Sandercock, S. Trelle, O. Weingart, S. Bayliss, B. Djulbegovic, C. L. Bennett, S. Langensiepen, C. Hyde, A. Engert, Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients, JNCI Journal of the National Cancer Institute, 2006, 98, 10, 708

    CrossRef

  25. 25
    C. Bokemeyer, K. Oechsle, J.-T. Hartmann, Anaemia in cancer patients: pathophysiology, incidence and treatment, European Journal of Clinical Investigation, 2005, 35,
  26. You have free access to this content26
    David H. Henry, Anemia in Patients With Cancer or Undergoing Cancer Therapy: Impact and Current Treatment Practice, Transfusion Alternatives in Transfusion Medicine, 2005, 6, 3
  27. 27
    Barbra J. Sasu, Cynthia Hartley, Henry Schultz, Patricia McElroy, Raheemuddin Khaja, Steven Elliott, Joan C. Egrie, Jeffrey K. Browne, C. Glenn Begley, Graham Molineux, Comparison of Epoetin Alfa and Darbepoetin Alfa Biological Activity under Different Administration Schedules in Normal Mice, Acta Haematologica, 2005, 113, 3, 163

    CrossRef

  28. 28
    James H Rosberg, Rym Ben-Hamadi, Pierre Y Cremieux, John M Fastenau, Catherine Tak Piech, Dose Conversion and Cost???Effectiveness of Erythropoietic???Therapies in Chemotherapy-Related Anaemia, Clinical Drug Investigation, 2005, 25, 1, 33

    CrossRef

  29. 29
    John Glaspy, David Henry, Ravi Patel, Simon Tchekmedyian, Steve Applebaum, Donald Berdeaux, Richard Lloyd, Russell Berg, Matt Austin, Greg Rossi, Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa, European Journal of Cancer, 2005, 41, 8, 1140

    CrossRef

  30. 30
    John A. Glaspy, Every-Three-Week Erythropoietic Support During Chemotherapy for Cancer: Current Status and Future Issues, Supportive Cancer Therapy, 2005, 3, 1, 16

    CrossRef

  31. 31
    Eric Pujade-Lauraine, Clare Topham, Once-Weekly Treatment of Anemia in Patients with Cancer: A Comparative Review of Epoetins, Oncology, 2005, 68, 2-3, 122

    CrossRef

  32. 32
    Johan Vansteenkiste, Isabelle Wauters, The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia, Expert Opinion on Pharmacotherapy, 2005, 6, 3, 429

    CrossRef

  33. 33
    Richard Booton, Nick Thatcher, The Value of Erythropoietin Therapy in Cancer Patients, American Journal of Cancer, 2005, 4, 2, 87

    CrossRef

  34. 34
    David J. Straus, Treatment of Anemia with Erythropoietic Agents in Patients with Hematologic Malignancies, Supportive Cancer Therapy, 2005, 2, 4, 215

    CrossRef

  35. 35
    Ronald J Trent, Molecular Medicine, 2005,

    CrossRef

  36. 36
    Anthony Morreale, Melissa De Lattre, Dan Boggie, Monica Schaefer, Clinical and economic comparison of epoetin alfa and darbepoetin alfa, Current Medical Research and Opinion, 2004, 20, 3, 381

    CrossRef

  37. 37
    C. Bokemeyer, M.S. Aapro, A. Courdi, J. Foubert, H. Link, A. Österborg, L. Repetto, P. Soubeyran, EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer, European Journal of Cancer, 2004, 40, 15, 2201

    CrossRef

  38. 38
    Bertrand Coiffier, Epoetin once weekly in anaemic patients with cancer, British Journal of Haematology, 2004, 125, 1
  39. 39
    William A. Thames, Sandra L. Smith, Andrew C. Scheifele, Bin Yao, Suzana A. Giffin, Julie L. Alley, Evaluation of the US Oncology Network's Recommended Guidelines for Therapeutic Substitution with Darbepoetin alfa 200 μg Every 2 Weeks in Both Naïve Patients and Patients Switched from Epoetin alfa, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2004, 24, 3
  40. 40
    Robin K Ohls, Aihua Dai, Long-acting erythropoietin: clinical studies and potential uses in neonates, Clinics in Perinatology, 2004, 31, 1, 77

    CrossRef

  41. 41
    Anders Österborg, New erythropoietic proteins: rationale and clinical data, Seminars in Oncology, 2004, 31, 12

    CrossRef

  42. 42
    Roger J. Waltzman, Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms, Seminars in Hematology, 2004, 41, 9

    CrossRef

  43. 43
    SIMON D ROGER, BRUCE COOPER, What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?, Nephrology, 2004, 9, 4
  44. 44
    Roberto Stasi, Luca Abriani, Patrizia Beccaglia, Edmondo Terzoli, Sergio Amadori, Cancer-related fatigue, Cancer, 2003, 98, 9
  45. 45
    Johan Vansteenkiste, Gregory Rossi, MaryAnn Foote, Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia, Expert Opinion on Biological Therapy, 2003, 3, 3, 501

    CrossRef

  46. 46
    Michael Hedenus, Magnus Adriansson, Jesus San Miguel, Mark H. H. Kramer, Martin R. Schipperus, Eeva Juvonen, Kerry Taylor, Andrew Belch, Albert Altés, Giovanni Martinelli, David Watson, James Matcham, Gregory Rossi, Timothy J. Littlewood, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study, British Journal of Haematology, 2003, 122, 3
  47. 47
    Michael Bloomfield, George Jaresko, John Zarek, Nicki Dozier, Guidelines for Using Darbepoetin alfa in Patients with Chemotherapy-Induced Anemia, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003, 23, 12P2
  48. 48
    Jesús F. San Miguel, Ramón García-Sanz, Myeloma: Update on supportive care strategies, Current Treatment Options in Oncology, 2003, 4, 3, 247

    CrossRef

  49. 49
    Salvatore Siena, Simona Secondino, Laura Giannetta, Ornella Carminati, Paolo Pedrazzoli, Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy, Critical Reviews in Oncology/Hematology, 2003, 48, S39

    CrossRef

  50. 50
    Jens Samol, Timothy J. Littlewood, The Efficacy of rHuEPO in Cancer-Related Anaemia, British Journal of Haematology, 2003, 121, 1
  51. 51
    J Bohlius, S Langensiepen, G Schwarzer, J Seidenfeld, M Piper, C Bennet, A Engert, Erythropoietin for patients with malignant disease, The Cochrane Library,
  52. 52
    Thomy Tonia, Annette Mettler, Nadège Robert, Guido Schwarzer, Jerome Seidenfeld, Olaf Weingart, Chris Hyde, Andreas Engert, Julia Bohlius, Erythropoietin or darbepoetin for patients with cancer, The Cochrane Library,
  53. 53
    Julia Bohlius, Jayne Wilson, Jerome Seidenfeld, Margret Piper, Guido Schwarzer, Josie Sandercock, Sven Trelle, Olaf Weingart, Susan Bayliss, Susan Brunskill, Benjamin Djulbegovic, Charles Bennett, Simon Langensiepen, Chris Hyde, Andreas Engert, Erythropoietin or Darbepoetin for patients with cancer, The Cochrane Library,
  54. 54
    Julia Bohlius, Kurt Schmidlin, Corinne Brillant, Guido Schwarzer, Sven Trelle, Jerome Seidenfeld, Marcel Zwahlen, Mike J Clarke, Olaf Weingart, Sabine Kluge, Margaret Piper, Maryann Napoli, Dirk Rades, David Steensma, Benjamin Djulbegovic, Martin F Fey, Isabelle Ray-Coquard, Volker Moebus, Gillian Thomas, Michael Untch, Martin Schumacher, Matthias Egger, Andreas Engert, Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data, The Cochrane Library,